Zorevunersen, an experimental gene therapy developed by Stoke Therapeutics and Biogen, reduced seizure frequency by up to 91% in children with Dravet syndrome, according to results published in the New England Journal of Medicine on March 4. The trial involved 81 children aged 2-18 in the UK and US, who experienced an average of 17 seizures per month before treatment.

The drug works by boosting protein production from a healthy copy of the SCN1A gene, addressing the root genetic cause of the condition. Children receiving a 70mg dose showed the greatest improvement, with seizure reductions between 59% and 91% over 20 months. Quality of life improved significantly, and most side effects were mild.

"This new treatment could help children with Dravet syndrome lead much healthier and happier lives," said Professor Helen Cross of UCL Institute of Child Health. A Phase Three study is currently underway.